[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hrr-gene-mutation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hrr-gene-mutation":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100497763",false,"NCT05761470","Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation","A Phase II Study of Camrelizumab, Fluzoparib and Nab-paclitaxel in Neoadjuvant Therapy of Her-2 Negative Breast Cancer Patients With HRR Gene Mutation","IMPARP","Inclusion Criteria:\n\n* Histologically documented Her-2 negative\n* TNM stage: T1c, N1-N2；T2-4, N0-N2；any T, N3\n* No distant metastatic disease\n* Eastern Cooperative Oncology Group Performance Status: 0\\~1\n* HRR gene mutation: at least one pathogenic or likely pathogenic variant in germline or somatic BRCA1, BCRA2 and PALB2 genes, or in germline ATM, BARD1, BRIP1, CDK12, CHEK2, RAD51C, RAD51D genes.\n\nExclusion Criteria:\n\n* Patients who are pregnant or lactating at the time of randomization or refuse to contraception.\n* Patients who have other malignant diseases within 2 years, except for cured skin basal cell carcinoma, breast carcinoma in situ or cervical carcinoma in situ\n* Patients with psychiatric disorder, peripheral or central nerve system disease or any disorder, which compromises ability to give informed consent or participate in this study.\n* Patients who have myocardial infarction or congestive heart failure, or other serious cardiac disease.\n* Patients who have used immunosuppressive drug or corticosteroids within 14 days.\n* Patients who have other diseases which researchers.\n* Patients who allergy to any of the drugs in this trail.","ALL","18 Years","75 Years",{"count":20,"type":21},66,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is to evaluate the efficacy and safety of combination of Camrelizumab (Immunotherapy, PD-1 inhibitor), Fluzoparib (PARP inhibitor) and Nab-paclitaxel in neoadjuvant therapy of Her-2 negative breast cancer patients with HRR gene mutation.",[27,28],"Her-2 Negative Breast Cancer","HRR Gene Mutation","RECRUITING","2023-03-07",{"date":32,"type":33},"2023-03-09","ACTUAL",{"date":35,"type":33},"2022-05-06",{"date":37,"type":21},"2028-12-31",{"name":39,"class":40},"Ying Lin","OTHER",""]